Mental Disorders

274 trials 116 recruiting

Filter these 274 trials by phase, country and sponsor.

Open in Search →

CIRAANO: Multimodal exploration of theater actors, memory athletes, and patients with various memory pathologies: evaluation of mnesic strat… Pending

2025-523264-21-00 Semantic Variant Primary Progressive Aphasia 10
Early mental response to hormonal treatment in transgender men - The EMRE Study Pending

2024-517052-35-00 Transsexual 6
OSU6162 in Bipolar Depression: An Open-label, Flexible Dose Study (OBID) Pending

2024-517560-30-00 Bipolar depression 4
Electrophysiological analysis of Gamma-Hydroxybutyrate-induced sleep in intensive care patients: A Pilot Double-Blind Randomized Controlled … Pending

2025-521967-11-00 The study population includes adult ICU patients with a 4
EFFECTIVENESS OF SUPPLEMENTATION WITH VITAMIN D IN PATIENTS WITH DEPRESSIVE DISORDER OR BIPOLAR DISORDER: A RANDOMIZED CONTROLLED CLINICAL T… Pending

2025-520778-20-00 Depressive disorder 11
SHIELD – Swift Hydrocortisone Intervention after trauma exposure Pending

2025-523350-13-02 Posttraumatic Stress Disorder (PTSD) 4
Oxytocin for drug relapse prevention Pending

2023-504518-31-01 substance use disorder 4
A study for adolescents who are depressed and thinking of suicide Recruiting

2024-518615-19-00 Major Depressive Disorder 5 2026-04-22
A Phase 3 Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Bipol… Recruiting

2025-521845-26-00 BP-I mania or mania with mixed features 5 2026-03-02
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder Recruiting

2025-523202-32-00 Major Depressive Disorder 5 2026-02-26
Evenamide in patients with treatment-resistant schizophrenia not responding to antipsychotics Recruiting

2024-519836-18-00 treatment-resistant schizophrenia (TRS) 5 2025-12-16
Long-Term Safety and Tolerability of NBI-1117568 in Adults with Schizophrenia Recruiting

2025-521216-19-00 Schizophrenia 5 2025-12-10
A Phase 3 Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer’s Disease Recruiting

2025-520746-30-00 Mild to moderate Alzheimer’s Disease 5 2025-11-18
Long-term study to assess the safety and tolerability of adjunctive NBI-1065845 in adults with Major Depressive Disorder (MDD) Recruiting

2024-519423-24-00 Major Depressive Disorder 5 2025-10-07
A Phase 3 Open-label Extension Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder Recruiting

2024-520259-26-00 Mania or Mania with Mixed Features in Bipolar-I Disorde 5 2025-09-25
A Phase 3 Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder Recruiting

2024-520195-94-00 BP-I mania or mania with mixed features 5 2025-09-25
A Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Monotherapy Study of the Efficacy, Safety, and Tolerability of SPT-300 in Ad… Recruiting

2025-521240-37-00 Major Depressive Disorder (MDD), with or without Anxiou 4 2025-09-11
Melatonin versus quetiapine in adolescents (MEL-QUE-A) Recruiting

2024-519597-39-00 Psychiatric disorder (ICD-10 F20-F69, F84, F90-F95) and 10 2025-08-18
A randomised, controlled trial to investigate the effect of a six-week intensified pharmacological treatment for bipolar depression compared… Recruiting

2023-506605-19-00 Bipolar depression 5 2025-02-11
Sodium-oxybate as a potential new treatment for catatonia in patients with depression, bipolar disorder or a psychotic disorder, a randomize… Recruiting

2024-517805-10-01 Catatonia 5 2024-11-12
A randomised, controlled trial to investigate the effect of a six-week intensified pharmacological treatment for schizophrenia compared to t… Recruiting

2023-506602-39-00 schizophrenia, schizoaffective disorder, schizophrenifo 6 2024-08-01
Safety and pharmacokinetics of antipsychotics in children 2: Studying TDM in an RCT Recruiting

2024-511568-96-00 Autism spectrum disorder 6 2024-07-16
Acute Effects of Partial GABA(A)-Receptor Modulation by GT-002 on Psychophysiological Measures: The TOTEMS Phase II Clinical Trial Targeting… Recruiting

2024-519389-28-00 Patients must meet diagnostic criteria for schizophreni 4 2026-05-07
The M-bipolar RCT Recruiting

2025-523549-92-00 Bipolar disorder 11 2026-04-16